High Affinity Nerve Growth Factor Receptor (Neurotrophic
Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or
Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140
TrkA or NTRK1 or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth
analysis on High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine
Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or
Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140
TrkA or NTRK1 or EC 2.7.10.1) targeted pipeline therapeutics.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/619222-high-affinity-nerve-growth-10-1-pipeline
The report provides comprehensive information on the High
Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor
Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related
Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC
2.7.10.1), targeted therapeutics, complete with analysis by indications, stage
of development, mechanism of action (MoA), route of administration (RoA) and
molecule type. The report also covers the descriptive pharmacological action of
the therapeutics, its complete research and development history and latest news
and press releases. Additionally, the report provides an overview of key
players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic
Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or
Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140
TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics development and features
dormant and discontinued projects.
Report features
investigational drugs from across globe covering over 20 therapy areas and
nearly 3,000 indications. Drug profiles featured in the report undergoes
periodic review following a stringent set of processes to ensure that all the
profiles are updated with the latest set of information. Additionally, various
dynamic tracking processes ensure that the most recent developments are
captured on a real time basis.
The report helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic
landscape for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine
Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or
Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140
TrkA or NTRK1 or EC 2.7.10.1)
- The report reviews High Affinity Nerve Growth Factor
Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming
Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase
Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted
therapeutics under development by companies and universities/research
institutes based on information derived from company and industry-specific
sources
- The report covers pipeline products based on various
stages of development ranging from pre-registration till discovery and
undisclosed stages
- The report features descriptive drug profiles for the
pipeline products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in High Affinity
Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or
TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or
Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)
targeted therapeutics and enlists all their major and minor projects
- The report assesses High Affinity Nerve Growth Factor
Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming
Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase
Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted
therapeutics based on mechanism of action (MoA), route of administration (RoA)
and molecule type
- The report summarizes all the dormant and discontinued
pipeline projects
- The report reviews latest news and deals related to High
Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor
Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related
Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC
2.7.10.1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis,
and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and
indications for High Affinity Nerve Growth Factor Receptor (Neurotrophic
Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or
Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140
TrkA or NTRK1 or EC 2.7.10.1)
- Identify the use of drugs for target identification and
drug repurposing
- Identify potential new clients or partners in the target
demographic
- Develop strategic initiatives by understanding the focus
areas of leading companies
- Plan mergers and acquisitions effectively by identifying
key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by
understanding High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine
Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or
Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140
TrkA or NTRK1 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive
projects to enhance and expand business potential and scope
Table of
Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
High Affinity Nerve Growth Factor Receptor (Neurotrophic
Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or
Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140
TrkA or NTRK1 or EC 2.7.10.1) Overview 9
Therapeutics Development 10
High Affinity Nerve Growth Factor Receptor (Neurotrophic
Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or
Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140
TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by Stage of
Development 10
High Affinity Nerve Growth Factor Receptor (Neurotrophic
Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or
Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140
TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by Therapy Area 11
High Affinity Nerve Growth Factor Receptor (Neurotrophic
Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or
Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140
TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by Indication 12
High Affinity Nerve Growth Factor Receptor (Neurotrophic
Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or
Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140
TrkA or NTRK1 or EC 2.7.10.1) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
High Affinity Nerve Growth Factor Receptor (Neurotrophic
Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or
Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140
TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by Companies 16
High Affinity Nerve Growth Factor Receptor (Neurotrophic
Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or
Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140
TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by
Universities/Institutes 21
High Affinity Nerve Growth Factor Receptor (Neurotrophic
Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or
Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140
TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Assessment 23
Access Report @ https://www.wiseguyreports.com/reports/619222-high-affinity-nerve-growth-10-1-pipeline
Contact Info:
NORAH TRENT
Partner Relations
& Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get
in touch:
LinkedIn:
www.linkedin.com/company/4828928
Twitter:
https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
No comments:
Post a Comment